Press release from Companies

Published: 2021-05-14 08:30:00

Double Bond Pharmaceutical International AB: DBP International: The Investigator’s Brochure for the SI-053 phase I trial is finalized


Double Bond Pharmaceutical International AB (publ) (“DBP”) takes a step further towards the start of the phase 1 clinical trial of its front-line product SI-053 in patients with glioblastoma - the Investigator’s Brochure (IB) for the coming trial is now compiled.

The Investigator’s Brochure (IB) is a comprehensive compilation of pre-clinical and nonclinical data regarding SI-053 maintained by DBP, that contains the body of information about the investigational product obtained before clinical trial. The IB is a document of critical importance throughout the drug development process and is updated with new information as it becomes available. The purpose of the IB is to compile data relevant to studies of SI-053 in human subjects gathered during preclinical and other clinical trials to provide the investigator with information necessary for the management of study conduct and study subjects throughout a clinical trial.

Preparation of the IB was accomplished in close collaboration with Investigators as well as contract research organization, CATO SMS, and in accordance with advice from scientific advising meeting with European Medicines Agency (EMA) (

"The completion of the IB is an important milestone in the development of SI-053 and we are very pleased to come even closer to start of the clinical study,” - comments Igor Lokot, CEO of DBP.


10 communicated milestones between Q3 2020 to Q2 2021

Milestone Comments Status
Preclinical: Efficacy of SI-053 in subcutaneous tumor in mice Finalized Done
Preclinical: Biodistribution of SI053 after intracerebral administration in rats Finalized Done
Preclinical: Toxicity studies of SI-053 after intracerebral administration in rats Finalized Done
Clinical: Key Opinion Leader (KOL) meeting, an important milestone for SI-053 Phase 1 clinical study Finalized Done
Clinical: Feasibility studies for clinical site selection for Phase 1 SI-053 clinical study Finalized Done
CMC: Sterilization of SI-053 will be validated Finalized Done
CMC: Stability study for SI-053 has been started Finalized Done
CMC: The IMPD is completed Q2 2021
Regulatory: Clinical trial application (CTA) for Phase 1 SI-053 clinical study Q2 2021
Financing phase 1 Q2 2021 – issuance of units as a probable alternative


More about Temodex/SI-053: Temodex, which is a locally acting formulation of temozolomide developed by RI PCP in Minsk, Belarus, is registered for marketing as the first-line treatment of glioblastoma within Belarus since 2014. Temodex was acquired by DBP in autumn 2015 and is now being prepared under the name SI-053 to pass through all the tests and trials required for registration within the EU and globally. Video presentation:

Information about Double Bond Pharmaceutical International AB:

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.


Full Company Name:   Double Bond Pharmaceutical International AB (publ)

Corporate identity:       556991-6082

Stock short name:       DBP B

Share ISIN code:          SE0007185525

For more info, contact

Igor Lokot, CEO



Follow us on LinkedIn and Twitter!


Läs mer hos Cision
Read more about Double Bond Pharmaceutical International AB